Play Video
1
Will AstraZeneca
Will AstraZeneca's ticagrelor make Effient and Plavix obsolete?
::2009/10/02::
Play Video
2
Translating Ticagrelor
Translating Ticagrelor's Pharmacokinetics
::2013/05/17::
Play Video
3
Prasugrel and Ticagrelor in STEMI Patients
Prasugrel and Ticagrelor in STEMI Patients
::2013/04/10::
Play Video
4
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on ...
New Sub-Analysis of PLATO ACS Study Suggests Patient Types and Stent Types Had No Impact on ...
::2013/08/05::
Play Video
5
Benefit of Ticagrelor in Plato - Clinical Implications
Benefit of Ticagrelor in Plato - Clinical Implications
::2013/05/16::
Play Video
6
BRILINTA (ticagrelor) Launches "Complete the Course"  ...
BRILINTA (ticagrelor) Launches "Complete the Course" ...
::2012/09/19::
Play Video
7
Ticagrelor Trumps Clopidogrel for Vascular and Bleeding Outcomes
Ticagrelor Trumps Clopidogrel for Vascular and Bleeding Outcomes
::2012/09/27::
Play Video
8
Flash Lecture: Ticagrelor vs. Clopidogrel in Patients with Stroke or TIA
Flash Lecture: Ticagrelor vs. Clopidogrel in Patients with Stroke or TIA
::2012/03/12::
Play Video
9
Ticagrelor Effects on MI Outcomes and Event Adjudication in PLATO
Ticagrelor Effects on MI Outcomes and Event Adjudication in PLATO
::2014/04/18::
Play Video
10
Uso del ticagrelor en el síndrome coronario agudo
Uso del ticagrelor en el síndrome coronario agudo
::2013/02/23::
Play Video
11
Prasugrel y Ticagrelor en SCA
Prasugrel y Ticagrelor en SCA
::2012/06/20::
Play Video
12
The Effect of Ticagrelor in ACS -- Platelet and Non Platelet Dependent  Mechanisms | Doron Zahger
The Effect of Ticagrelor in ACS -- Platelet and Non Platelet Dependent Mechanisms | Doron Zahger
::2014/06/09::
Play Video
13
hm_Apixaban, Ticagrelor Both Winners
hm_Apixaban, Ticagrelor Both Winners
::2013/01/08::
Play Video
14
WEBM Dra  Camila Ramos nuevos antiagregantes ticagrelor y praugrel
WEBM Dra Camila Ramos nuevos antiagregantes ticagrelor y praugrel
::2014/04/21::
Play Video
15
Nuevo Antiagregantes: Prasugrel y Ticagrelor XIV Congreso SEMES CV
Nuevo Antiagregantes: Prasugrel y Ticagrelor XIV Congreso SEMES CV
::2011/11/29::
Play Video
16
Why do I Use Ticagrelor in STEMI Patients | Elad Asher
Why do I Use Ticagrelor in STEMI Patients | Elad Asher
::2014/06/09::
Play Video
17
The PLATO STEMI subanalysis: Will ticagrelor become the new go-to drug for antiplatelet therapy?
The PLATO STEMI subanalysis: Will ticagrelor become the new go-to drug for antiplatelet therapy?
::2010/04/30::
Play Video
18
Ticagrelor: de la teoría a la práctica. Experiencia de uso en el día a día. Dr. Radke
Ticagrelor: de la teoría a la práctica. Experiencia de uso en el día a día. Dr. Radke
::2012/10/19::
Play Video
19
Over-the-Top Brilinta (ticagrelor) Pharma Display
Over-the-Top Brilinta (ticagrelor) Pharma Display
::2014/03/29::
Play Video
20
The PLATO CABG analysis: Another feather in the cap for ticagrelor?
The PLATO CABG analysis: Another feather in the cap for ticagrelor?
::2010/08/19::
Play Video
21
Impatto della somministrazione di ticagrelor in ambulanza nei pazienti con infarto
Impatto della somministrazione di ticagrelor in ambulanza nei pazienti con infarto
::2014/09/06::
Play Video
22
7  Steg
7 Steg
::2014/04/03::
Play Video
23
Insidermedicine In 60 - January 13, 2010
Insidermedicine In 60 - January 13, 2010
::2010/01/14::
Play Video
24
Aterosclerosi e Trombosi - Meccanismi fisiopatologici e progressi clinici
Aterosclerosi e Trombosi - Meccanismi fisiopatologici e progressi clinici
::2013/01/16::
Play Video
25
GLOBAL LEADERS STUDY
GLOBAL LEADERS STUDY
::2013/05/16::
Play Video
26
CV drugs interaction
CV drugs interaction
::2014/02/11::
Play Video
27
The QAS Coronary Artery Reperfusion CPP
The QAS Coronary Artery Reperfusion CPP
::2014/04/29::
Play Video
28
Modulo SCACEST
Modulo SCACEST
::2014/04/08::
Play Video
29
Kim Kelly, question 3
Kim Kelly, question 3
::2013/02/25::
Play Video
30
Michael Callaghan, question 3
Michael Callaghan, question 3
::2013/02/27::
Play Video
31
Prof. Gilles Montalescot, Pitié-Salpetrière University Hospital (Paris, France)
Prof. Gilles Montalescot, Pitié-Salpetrière University Hospital (Paris, France)
::2014/09/01::
Play Video
32
Rachel Harris, question 3
Rachel Harris, question 3
::2013/02/25::
Play Video
33
High-Sensitivity Troponin as a Biomarker: A PLATO Substudy
High-Sensitivity Troponin as a Biomarker: A PLATO Substudy
::2012/12/17::
Play Video
34
Stephanie Young, question 3
Stephanie Young, question 3
::2013/02/25::
Play Video
35
Dr. Scott Wilson, question 3
Dr. Scott Wilson, question 3
::2013/02/25::
Play Video
36
Outcomes and Costs Following CV Imaging: A SPARC, but More Illumination is Needed
Outcomes and Costs Following CV Imaging: A SPARC, but More Illumination is Needed
::2014/04/17::
Play Video
37
Michael Callaghan, question 4
Michael Callaghan, question 4
::2013/02/27::
Play Video
38
AR Post TAVR
AR Post TAVR
::2013/04/10::
Play Video
39
Flash Lecture: HDL as a predictor of new HF
Flash Lecture: HDL as a predictor of new HF
::2012/01/20::
Play Video
40
Dia_internacional_del_donante_de_sangre.mpg
Dia_internacional_del_donante_de_sangre.mpg
::2011/06/27::
Play Video
41
3 VIDEO Valeria
3 VIDEO Valeria
::2014/02/09::
Play Video
42
Aula de Pacients. Tractament farmacològic de la FPI. 25 de juny de 2013. Sessió 3 de 4
Aula de Pacients. Tractament farmacològic de la FPI. 25 de juny de 2013. Sessió 3 de 4
::2013/08/16::
Play Video
43
Omg Atlanta
Omg Atlanta
::2014/02/14::
Play Video
44
Stephanie Young, question 4
Stephanie Young, question 4
::2013/02/25::
Play Video
45
Unmet needs in acute cardiac care Wijns&Clemmensen
Unmet needs in acute cardiac care Wijns&Clemmensen
::2013/10/07::
Play Video
46
Edited_Acute Coronary Syndromes_Excerpt_TRT:4:22
Edited_Acute Coronary Syndromes_Excerpt_TRT:4:22
::2008/01/03::
Play Video
47
About CABG Me.MPG
About CABG Me.MPG
::2010/05/12::
Play Video
48
Challenges for Post-PCI Antiplatelet Drugs
Challenges for Post-PCI Antiplatelet Drugs
::2012/04/23::
Play Video
49
Clot formation & Clopidogrel MOA
Clot formation & Clopidogrel MOA
::2013/03/19::
Play Video
50
FDA on the Brilinta approval
FDA on the Brilinta approval
::2011/07/26::
MAIS >>
RESULTADOS [51 .. 101]
Origem: Wikipédia, a enciclopédia livre.
Ir para: navegação, pesquisa
Ticagrelor
Alerta sobre risco à saúde
Ticagrelor.svg
Nome IUPAC (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-
3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-
hydroxyethoxy)cyclopentane-1,2-diol
Outros nomes AZD6140
Identificadores
Número CAS 274693-27-5
PubChem 9871419
Propriedades
Fórmula química C23H28F2N6O4S
Massa molar 522.55 g mol-1
Farmacologia
Via(s) de administração oral
Excepto onde denotado, os dados referem-se a
materiais sob condições PTN

Referências e avisos gerais sobre esta caixa.
Alerta sobre risco à saúde.

Ticagrelor (nome comercial Brilinta) é um fármaco inibidor da agregação plaquetária produzido pela AstraZeneca.[1]

Notas e referências

  1. RCM Pharma. Ticagrelor pertence a uma classe pioneira de medicamentos para tratamento antiplaquetário mais eficaz, proporcionando redução de eventos trombóticos em pacientes com síndrome coronariana aguda (SCA), também conhecidos como infarto ou angina instável (dor no peito). Painel da FDA com opiniões divergentes sobre o Brilinta® da AstraZeneca. Acesso em 29 de julho de 2010
Ícone de esboço Este artigo sobre fármacos é um esboço. Você pode ajudar a Wikipédia expandindo-o.
Conteúdo da Wikipedia está licenciado sob a: GFDL License
Powered by YouTube